Coherus Biosciences (CHRS) AI Stock Analysis

• Market Cap: $161.97M
• Dividend Yield: N/A
• Average Volume (3M): 1.15M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.10
• Revenue Growth: -72.54%
• EPS Growth: -19972.15%
• Country: US
• Employees: 228
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.31
• Shares Outstanding: 120,871,010
• 10 Day Avg. Volume: 1,404,162
• 30 Day Avg. Volume: 1,152,916
• PEG Ratio: -0.05
• Price to Book (P/B): -1.20
• Price to Sales (P/S): 0.59
• P/FCF Ratio: -7.73
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $5.50
• Price Target Upside: 310.45% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -1.51
• Revenue Forecast (FY): $46.27M

• Rating: 46 Neutral
• Price Target: $1.50 ▲(11.94% Upside)

The overall stock score is primarily impacted by significant financial challenges, including declining revenue and profitability, high leverage, and cash flow issues. Technical analysis also indicates bearish momentum. However, the earnings call provides some optimism with strategic initiatives and pipeline progress, slightly offsetting the negative financial performance.

Positive Factors

Pipeline Progress

The advancement of clinical trials and the pursuit of multiple cancer indications demonstrate Coherus' scientific leadership and potential for future revenue growth.

Market Expansion

Expanding the sales force and implementing a remote team will enhance market penetration, potentially increasing sales and market share in the long term.

Balance Sheet Improvement

Improved debt-to-equity ratio enhances financial stability and flexibility, allowing Coherus to invest in growth opportunities without excessive financial risk.

Negative Factors

Declining Revenue

Declining revenue and profitability indicate operational challenges and may hinder the company's ability to invest in growth and innovation.

Cash Flow Challenges

Negative cash flows can limit Coherus' ability to fund operations and strategic initiatives, potentially impacting long-term growth and stability.

Community Engagement Issues

Low awareness among community physicians can limit market penetration and sales growth, affecting the company's ability to expand its customer base.

Coherus Biosciences Business Overview & Revenue Model

Company Description

Coherus Biosciences (CHRS) is a biotechnology company focused on developing and commercializing innovative biologic medicines. The company specializes in biosimilars, which are biologic medical products highly similar to already approved reference products, aimed at improving patient access to essential therapies. Coherus operates primarily in the oncology and autoimmune disease sectors, offering a range of products that include both FDA-approved biosimilars and a robust pipeline of candidates in various stages of development.

How the Company Makes Money

Coherus Biosciences generates revenue primarily through the sale of its biosimilar products. The company has established key partnerships with other pharmaceutical companies to enhance its research and development capabilities and expand its market reach. Significant revenue streams include product sales from its approved biosimilars, royalties from collaborations, and potential milestone payments associated with its pipeline products. Additionally, the company may benefit from expanding its portfolio of biosimilars as it seeks to capture market share in the growing biosimilars market, which is driven by increasing demand for cost-effective biologic therapies.

Coherus Biosciences Financial Statement Overview

Summary

Coherus Biosciences is facing substantial financial challenges across all verticals. The income statement shows declining revenue and profitability, the balance sheet indicates high leverage and negative equity returns, and cash flow statements reveal significant cash management issues. The company needs to address these operational and financial inefficiencies to stabilize its financial health.

Income Statement

The income statement shows a concerning trend with declining revenue and profitability. The TTM data indicates a significant revenue drop of 27.7%, and the net profit margin is highly volatile, showing a large positive due to non-operational factors. Gross profit margin remains relatively stable, but EBIT and EBITDA margins are negative, indicating operational challenges.

Balance Sheet

The balance sheet reflects a mixed picture. The debt-to-equity ratio has improved significantly in the TTM period, indicating reduced leverage. However, the return on equity is negative, suggesting inefficiencies in generating returns from equity. The equity ratio is not favorable, indicating potential financial instability.

Cash Flow

Cash flow analysis reveals significant challenges. The TTM period shows negative operating and free cash flows, with a dramatic decline in free cash flow growth. The operating cash flow to net income ratio is negative, indicating cash flow issues relative to reported earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	83.57M	266.96M	257.24M	211.04M	326.55M	475.82M
Gross Profit	32.09M	149.41M	98.25M	140.96M	268.96M	438.16M
EBITDA	-174.42M	60.94M	-193.94M	-255.58M	-260.69M	161.84M
Net Income	154.97M	28.51M	-237.89M	-291.75M	-287.10M	132.24M
Balance Sheet
Total Assets	516.52M	448.53M	629.60M	480.85M	679.33M	841.65M
Cash, Cash Equivalents and Short-Term Investments	191.66M	125.99M	117.75M	191.68M	417.19M	541.16M
Total Debt	1.95M	269.90M	480.84M	480.42M	419.02M	417.10M
Total Liabilities	428.75M	580.52M	823.03M	618.26M	581.61M	560.67M
Stockholders Equity	87.77M	-131.99M	-193.43M	-137.42M	97.73M	280.97M
Cash Flow
Free Cash Flow	-90.19M	-20.44M	-175.17M	-243.16M	-38.72M	147.09M
Operating Cash Flow	-90.19M	-20.44M	-174.88M	-241.12M	-37.43M	154.15M
Investing Cash Flow	377.38M	230.32M	144.64M	-166.85M	-138.41M	-14.40M
Financing Cash Flow	-281.56M	-186.97M	69.60M	54.33M	51.88M	223.95M

Coherus Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.34
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CHRS, the sentiment is Negative. The current price of 1.34 is below the 20-day moving average (MA) of 1.65, below the 50-day MA of 1.55, and above the 200-day MA of 1.10, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 33.61 is Neutral, neither overbought nor oversold. The STOCH value of 24.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CHRS.

Coherus Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PLX	69 Neutral	$174.61M	29.59	15.99%	―	62.79%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GNFT	48 Neutral	$206.09M	-4.79	-51.06%	―	-44.94%	-274.42%
CHRS	46 Neutral	$161.97M	―	-860.65%	―	-72.54%	-19972.15%
IPHA	46 Neutral	$162.51M	―	-271.32%	―	-75.77%	-31.24%
SLS	43 Neutral	$198.87M	―	-180.71%	―	―	64.43%
MCRB	42 Neutral	$125.38M	23.09	15.95%	―	448.44%	―

Coherus Biosciences Corporate Events

Coherus Oncology Reports Q3 2025 Financial Results

Coherus Oncology, Inc. is a commercial-stage biotechnology company specializing in innovative oncology therapies, with a focus on developing and commercializing treatments for various types of cancer. The company is known for its next-generation PD-1 inhibitor, LOQTORZI, and a robust pipeline of clinical candidates targeting multiple cancer indications.

Coherus Biosciences Regains Nasdaq Compliance

On June 30, 2025, Coherus Oncology, Inc. received a deficiency notice from Nasdaq due to its stock price falling below $1.00 per share for 30 consecutive business days. By September 5, 2025, the company regained compliance with Nasdaq’s listing requirements, ensuring its continued presence on the Nasdaq Global Market.

The most recent analyst rating on (CHRS) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Coherus Biosciences stock, see the CHRS Stock Forecast page.

Coherus Oncology’s Earnings Call Highlights Growth and Challenges

Coherus Oncology’s recent earnings call projected an optimistic outlook, underscored by robust revenue growth and successful strategic repositioning. Despite these positive developments, the company acknowledged challenges in community adoption and a reliance on future data readouts for continued success.

Coherus Oncology Reports Strong Q2 2025 Growth

Coherus Oncology is a commercial-stage oncology company focused on developing innovative cancer treatments, with a proprietary pipeline that includes LOQTORZI, a PD-1 inhibitor, and other promising candidates targeting various solid tumors. In its second-quarter 2025 earnings report, Coherus Oncology announced a significant 36% increase in net revenue for LOQTORZI, reaching $10 million, driven by increased patient demand and inventory restocking. The company also highlighted its strong cash position of $238 million, providing a runway through 2026 to support its ongoing clinical programs. Key financial metrics included a net loss from continuing operations of $44.9 million, an improvement from the previous year’s loss, and a substantial net income from discontinued operations due to the UDENYCA divestiture. Coherus is advancing its clinical pipeline with CHS-114 and casdozokitug, with data readouts expected in 2026, and aims to expand LOQTORZI’s market potential through strategic partnerships and label expansions. Looking ahead, Coherus remains focused on maximizing LOQTORZI’s potential and advancing its pipeline, with management optimistic about unlocking significant market opportunities and enhancing patient outcomes.